Imaging characterization of benign and malignant pheochromocytoma or paraganglioma: comparison between MIBG uptake and MR signal intensity ratio(372 views) Maurea S, Cuocolo A, Imbriaco M, Pellegrino T, Fusari M, Cuocolo R, Liuzzi R, Salvatore M
Ann Nucl Med (ISSN: 1864-6433, 0914-7187, 1864-6433electronic), 2012 Oct; 26(8): 670-675.
Department of Biomorphological and Functional Sciences, University Federico II, Naples, Italy. maurea@unina.it
Institute of Biostructures and Bioimages, National Council of Research, Naples, Italy
SDN Foundation, Institute of Diagnostic and Nuclear Development, Naples, Italy
References: Pacak, K., Eisenhofer, G., Ahlman, H., Bornstein, S.R., Gimenez-Roqueplo, A.-P., Grossman, A.B., Kimura, N., Tischler, A.S., Pheochromocytoma: Recommendations for clinical practice from the first international symposium (2007) Nature Clinical Practice Endocrinology and Metabolism, 3 (2), pp. 92-102. , DOI 10.1038/ncpendmet0396, PII NCPENDMET039
Lenders, J.W., Eisenhofer, G., Mannelli, M., Pacak, K., Pheochromocytoma (2005) Lancet., 366, pp. 665-675
Ra DeLellis Lloyd, R.V., Heitz, P.U., (2004) WHO Classification Of Tumours-pathology And Genetics Of Tumours Of Endocrine Organs, pp. 147-150. , Lyon: IARC Press
Gao, B., Kong, F., Xu, Z., Development of differential diagnosis for benign and malignant pheochromocytomas (2008) Int J Urol., 15, pp. 771-777
Kann, P.H., Wirkus, B., Behr, T., Klose, K.-J., Meyer, S., Endosonographic imaging of benign and malignant pheochromocytomas (2004) Journal of Clinical Endocrinology and Metabolism, 89 (4), pp. 1694-1697. , DOI 10.1210/jc.2003-031709
Mayo-Smith, W.W., Boland, G.W., Noto, R.B., Lee, M.J., State-of-Theart of adrenal imaging (2001) Radiographics., 21, pp. 995-1012
Maurea, S., Caraco, C., Castelli, L., Filice, S., Alfano, B., Ruffolo, F., Magnetic resonance in the study of suprarenal neoplasms. Qualitative and quantitative analysis of signal intensity (1998) Radiol Med., 95, pp. 199-207
Ilias, I., Sahdev, A., Reznek, R.H., Grossman, A.B., Pacak, K., The optimal imaging of adrenal tumours: A comparison of different methods (2007) Endocrine-Related Cancer, 14 (3), pp. 587-599. , DOI 10.1677/ERC-07-0045
Nguyen, H.H., Proye, C.A.G., Carnaille, B., Combemale, F., Pattou, F.N., Huglo, D., Tumour size: The only predictive factor for 131I MIBG uptake in phaeochromocytoma and paraganglioma (1999) Australian and New Zealand Journal of Surgery, 69 (5), pp. 350-353. , DOI 10.1046/j.1440-1622.1999.01570.x
Maurea, S., Cuocolo, A., Reynolds, J.C., Tumeh, S.S., Begley, M.G., Linehan, W.M., 131-I MIBG scintigraphy for monitoring response to chemotherapy in malignant pheochromocytoma: Comparison with urinary biochemical analysis (1991) J Nucl Med., 32, p. 1044
Maurea, S., Lastoria, S., Caraco, C., Klain, M., Varrella, P., Acampa, W., Muto, P., Salvatore, M., The role of radiolabeled somatostatin analogs in adrenal imaging (1996) Nuclear Medicine and Biology, 23 (6), pp. 677-680. , DOI 10.1016/0969-8051(96)00065-0
Van Der Harst, E., De Herder, W.W., Bruining, H.A., Bonjer, H.J., De Krijger, R.R., Lamberts, S.W.J., Van De Meiracker, A.H., Kwekkeboom, D.J., [123I]metaiodobenzylguanidine and [111In]octreotide uptake in benign and malignant pheochromocytomas (2001) Journal of Clinical Endocrinology and Metabolism, 86 (2), pp. 685-693. , DOI 10.1210/jc.86.2.685
Bomanji, J., Levison, D.A., Flatman, W.D., Uptake of iodine-123 MIBG by pheochromocytomas, paragangliomas, and neuroblastomas: A histopathological comparison (1987) Journal of Nuclear Medicine, 28 (6), pp. 973-978
McEwan, A.J., Shapiro, B., Sisson, J.C., Beierwaltes, W.H., Ackery, D.M., Radioiodobenzylguanidine for the scintigraphic location and therapy of adrenergic tumors (1985) Sem Nucl Med., 15, pp. 132-153
Jacques Jr., S., Tobes, M.C., Sisson, J.C., Sodium dependency of uptake of norepinephrine and m-iodobenzylguanidine into cultured human pheochromocytoma cells: Evidence for uptake-one (1987) Cancer Research, 47 (15), pp. 3920-3928
Loh, K.-C., Fitzgerald, P.A., Matthay, K.K., Yeo, P.P.B., Price, D.C., The treatment of malignant pheochromocytoma with iodine-131 metaiodobenzylguanidine (131I-MIBG): A comprehensive review of 116 reported patients (1997) Journal of Endocrinological Investigation, 20 (11), pp. 648-658
Rose, B., Matthay, K.K., Price, D., Huberty, J., Klencke, B., Norton, J.A., Fitzgerald, P.A., High-dose 131I-Metaiodobenzylguanidine therapy for 12 patients with malignant pheochromocytoma (2003) Cancer, 98 (2), pp. 239-248. , DOI 10.1002/cncr.11518
Chrisoulidou, A., Kaltsas, G., Ilias, I., Grossman, A.B., The diagnosis and management of malignant phaeochromocytoma and paraganglioma (2007) Endocrine-Related Cancer, 14 (3), pp. 569-585. , DOI 10.1677/ERC-07-0074
Timmers, H.J., Chen, C.C., Carrasquillo, J.A., Whatley, M., Ling, A., Havekes, B., Comparison of f-18 fluoro-l-dopa, f-18 fluoro-deoxyglucose, and f-18 fluorodopamine pet and i-123 mibg scintigraphy in the localization of pheochromocytoma and paraganglioma (2009) J Clin Endocrinol Metab., 94, pp. 4757-4767
Quint, L.E., Glazer, G.M., Francis, I.R., Shapiro, B., Chenevert, T.L., Pheochromocytoma and paraganglioma: Comparison of MR imaging with CT and I-131 MIBG scintigraphy (1987) Radiology, 165 (1), pp. 89-93
Van Gils, A.P.G., Van Erkel, A.R., Falke, T.H.M., Pauwels, E.K.J., Magnetic resonance imaging or metaiodobenzylguanidine scintigraphy for the demonstration of paragangliomas? Correlations and disparities (1994) European Journal of Nuclear Medicine, 21 (3), pp. 239-253
Lenders, J. W., Eisenhofer, G., Mannelli, M., Pacak, K., Pheochromocytoma (2005) Lancet., 366, pp. 665-675
Blake, M. A., Kalra, M. K., Maher, M. M., Sahani, D. V., Sweeney, A. T., Mueller, P. R., Hahn, P. F., Boland, G. W., Pheochromocytoma: An imaging chameleon (2004) Radiographics, 24 (SPEC. ISS.), pp. S87-S99
Kann, P. H., Wirkus, B., Behr, T., Klose, K. -J., Meyer, S., Endosonographic imaging of benign and malignant pheochromocytomas (2004) Journal of Clinical Endocrinology and Metabolism, 89 (4), pp. 1694-1697. , DOI 10. 1210/jc. 2003-031709
Mayo-Smith, W. W., Boland, G. W., Noto, R. B., Lee, M. J., State-of-Theart of adrenal imaging (2001) Radiographics., 21, pp. 995-1012
Nguyen, H. H., Proye, C. A. G., Carnaille, B., Combemale, F., Pattou, F. N., Huglo, D., Tumour size: The only predictive factor for 131I MIBG uptake in phaeochromocytoma and paraganglioma (1999) Australian and New Zealand Journal of Surgery, 69 (5), pp. 350-353. , DOI 10. 1046/j. 1440-1622. 1999. 01570. x
McEwan, A. J., Shapiro, B., Sisson, J. C., Beierwaltes, W. H., Ackery, D. M., Radioiodobenzylguanidine for the scintigraphic location and therapy of adrenergic tumors (1985) Sem Nucl Med., 15, pp. 132-153
Loh, K. -C., Fitzgerald, P. A., Matthay, K. K., Yeo, P. P. B., Price, D. C., The treatment of malignant pheochromocytoma with iodine-131 metaiodobenzylguanidine (131I-MIBG): A comprehensive review of 116 reported patients (1997) Journal of Endocrinological Investigation, 20 (11), pp. 648-658
Timmers, H. J., Chen, C. C., Carrasquillo, J. A., Whatley, M., Ling, A., Havekes, B., Comparison of f-18 fluoro-l-dopa, f-18 fluoro-deoxyglucose, and f-18 fluorodopamine pet and i-123 mibg scintigraphy in the localization of pheochromocytoma and paraganglioma (2009) J Clin Endocrinol Metab., 94, pp. 4757-4767
Quint, L. E., Glazer, G. M., Francis, I. R., Shapiro, B., Chenevert, T. L., Pheochromocytoma and paraganglioma: Comparison of MR imaging with CT and I-131 MIBG scintigraphy (1987) Radiology, 165 (1), pp. 89-93
Van Gils, A. P. G., Van Erkel, A. R., Falke, T. H. M., Pauwels, E. K. J., Magnetic resonance imaging or metaiodobenzylguanidine scintigraphy for the demonstration of paragangliomas? Correlations and disparities (1994) European Journal of Nuclear Medicine, 21 (3), pp. 239-253
Imaging characterization of benign and malignant pheochromocytoma or paraganglioma: comparison between MIBG uptake and MR signal intensity ratio
OBJECTIVE: We compared metaiodobenzylguanidine (MIBG) uptake and magnetic resonance (MR) signal intensity ratio in differentiating benign and malignant disease in patients with pheochromocytoma or paraganglioma.; METHODS: Eighteen patients (9 men, mean age 37 ± 8 years) with pheochromocytoma or paraganglioma underwent MR imaging and iodine-131 MIBG scintigraphy. MR signal intensity ratio was measured on T1 and T2-weighted images using region of interest analysis and intensity ratio of MIBG uptake was calculated for each tumor lesion on 48 h images.; RESULTS: A total of 28 tumor lesions was analyzed of which 12 were benign and 16 malignant. MIBG uptake intensity ratio was significantly higher in malignant lesions compared to benign (5.2 ± 2.4 and 2.9 ± 1.4, respectively, p < 0.01). On the contrary, no significant difference in tumor size and MR signal intensity ratio between malignant and benign tumor lesions was observed.; CONCLUSIONS: In patients with pheochromocytoma or paraganglioma, iodine-131 MIBG uptake is able to differentiate between benign and malignant disease, while MR imaging is not useful for this purpose. The higher MIBG uptake observed in malignant lesions could reflect major tumor storage of catecholamines compared to benign lesions.
Imaging characterization of benign and malignant pheochromocytoma or paraganglioma: comparison between MIBG uptake and MR signal intensity ratio
No results.
Imaging characterization of benign and malignant pheochromocytoma or paraganglioma: comparison between MIBG uptake and MR signal intensity ratio